To characterize the region on human IgG1 
wild-type IgG1 . This finding suggests that in addition to the primary contact site identified in the N terminus of the vl CH2 domain, secondary sites involving residues from the C-terminal half of the domain may also contribute to the IgGl-Fc,$I interaction.
Fc receptors for human IgGs (FcR) form a family of integral membrane proteins that specifically bind to immunoglobulin Fc regions.O The interaction of FcRs with IgG trigger critical host effector functions such as phagocytosis of immune complexes (1) , antibody-dependent cell-mediated cytotoxicity (2) (3) (4) , and the release of inflammatory mediators (5) .
Three classes of human FceR have been defined on the basis of their reactivity with monoclonal antibodies (6) . The high-affinity FcRI (CD64) is a 72-kDa glycoprotein expressed on mononuclear phagocytes (7) and interferon y-activated neutrophils (2) . FcRI displays a hierarchy of affinities for monovalent human IgG subclasses. IgG1 and IgG3 bind with high affinity (Ka 108-109 M-1), whereas IgG4 is 10-fold less cytophilic and IgG2 is devoid of any significant binding activity (8) .
Several indirect approaches suggest that the primary site that mediates the IgG1-FcXRI interaction resides within the heavy-chain constant region 2 (CH2) domain. Monoclonal antibodies directed against a CH2 domain N-terminal epitope including the isotype-specific residue K274, inhibited the IgG1-FcRI interaction (9) . Furthermore, the CH2 domaindeleted IgG1 myeloma protein TIM failed to bind FcXRI (10) .
Results obtained with isolated CH2 domains remain controversial since dimeric, but not monomeric, domains possess cytophilic activity (11, 12) . In the context of a hybrid molecule, however, only a single cytophilic H chain is required for binding activity (13) . More recently, the functional analysis of a panel of genetically engineered human IgG1/IgE hybrid antibodies indicated that the FcRI binding site was essentially a property of the IgG1 CH2 domain (14) . Several observations suggest that the CH2 N terminus forms at least part of the IgG1 FcXRI recognition site.
Comparative primary sequence analysis revealed that an LLGGP motif spanning residues 234-238 is conserved in all cytophilic IgGs (15) . Site-directed mutagenesis of E235 in noncytophilic mouse IgG2b to L235 produced the LLGGP motif on an IgG2b background, rendering this molecule fully active (16 MATERIALS AND METHODS Cell Lines. The murine myeloma A-chain-producing mutant cell line MOPC 315.26 was maintained as described (17) . U937 cells were grown in RPMI 1640 medium supplemented with 2% fetal calf serum, 2 mM glutamine, and antibiotics.
Plasmid Constructs. The pSV2neoVH315 mammalian expression vector has been described (18 Electroporation. The pSV2neoVH315 IgG1, IgG2, and IgG4 H-chain constructs were transfected into the A-chainproducing cell line MOPC 315.26 by electroporation according to the method ofBaker et al. (21) . The electroporated cells were grown and selected in G418 (GIBCO) (17) . Antibody production was quantified by IgG-specific capture ELISA, using myeloma human IgG1 and IgG2 as standards.
Assembly of Chimeric Molecules. The assembly of the chimeric antibodies was evaluated by SDS/polyacrylamide gradient (4-15%) gel electrophoresis under nonreducing conditions. Culture supernatants containing -5 ,g of chimeric immunoglobulin were incubated with 50 ,ul of a 10%o suspension of formalin-treated Staphylococcus aureus bacteria for 1 hr at 4°C. The pellets were washed six times in phosphatebuffered saline (PBS) containing 0.5% Triton X-100, 0.25% deoxycholate, 0.5% SDS, 10 mM EDTA, and 2 mM phenylmethylsulfonyl fluoride and then boiled for 3 min in 2x sample buffer containing 4% SDS and 1 mM iodoacetamide to prevent disulfide interchange. Preparation of Culture Supernatants for Binding Inhibition Assays. Culture supernatants were concentrated 10-fold using Centriprep-30 microconcentrators (Amicon). The concentrated culture supernatants were then subjected to ultracentrifugation for 30 min at 100,000 x g at 4°C to remove potential IgG aggregates. The final concentration of chimeric antibodies was assessed by triplicate ELISA determinations.
Binding Inhibition Studies. Purified human IgG1 myeloma protein was radioiodinated using Iodobeads (Pierce) to a specific activity of 1 x 106 cpm/,ug. Bound 1251 was separated from free material by gel filtration through a Biogel P4 spin column. IgG concentration was measured spectrophotometrically at 280 nm using an extinction coefficient E%1-"v of 1.4. U937 cells were washed once in PBS containing 0.02% sodium azide and bovine serum albumin (1 mg/ml) and resuspended in the same buffer. Direct binding and inhibition assays were carried out in 96-well U-bottom microtiter plates essentially as described by Raychaudhuri et al. (22) . In brief, for the inhibition assay, 2.5 x 106 U937 cells were incubated per well with 10 nM radiolabeled IgG1 and increasing concentrations of chimeric inhibitor for 2 hr at room temperature and then spun through a dibutyl phthalate oil cushion; cellular pellets were assayed for bound radioactivity. Nonspecific binding was determined from the residual bound radioactivity in the presence of 10 ,uM unlabeled IgG1 and never exceeded 2% of total binding. All values were corrected for nonspecific binding. The association constants of the chimeric antibodies were estimated from the displacement of the inhibition curve (at 50%) obtained with chimeric inhibitor relative to that obtained with myeloma IgG1 for which the Ka was determined in a direct binding assay (23) . Three independent determinations were obtained in triplicate for each chimera species. RESULTS Construction, Expression, and FcRI Binding Properties of Hybrid IgGl and IgG2 Antibodies. The role of individual domains in the cytophilic activity of human IgG isotypes was analyzed by exon-shuffling experiments. The panel of hybrid genes is depicted schematically in Fig. 1 . An IgG1 molecule with an IgG4 hinge was also constructed (data not shown). Hybrid molecules are described by four digit numbers indicating the subclass origin of the CH1, hinge, CH2, and CH3 exons, respectively.
Chimeric immunoglobulins from clones secreting in the range of 5-10 ,ug of IgG per ml were affinity isolated with S. aureus cells and analyzed by SDS/PAGE. Nonreduced SDS/ PAGE revealed that all molecules migrated as a single band with an apparent molecular mass of 150 kDa corresponding to a covalently assembled H2L2 molecule that could be dissociated into its constituent H and L chains upon reduction (data not shown). Representative electrophoretic patterns obtained with wild-type chimeric IgG1 and IgG2 and hybrid IgGl-1-2-1, IgG2-2-1-2 molecules are shown in Fig. 
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The binding properties of the exon-shuffled antibodies were assessed by competitive inhibition assays. To validate the use of chimeric IgGs as inhibitors, we confirmed that the cytophilic activity of the IgG1 chimera was indistinguishable from that of myeloma IgGI. Representative binding inhibition curves obtained for these molecules are depicted in Fig.  3A . The curves demonstrate a typical sigmoidal shape and are superimposable. This indicated that the Ka value for the chimeric IgG1 molecule was the same as that of myeloma IgGl, which was determined in an independent direct binding 11 Example of nomenclature for hybrid molecules: IgG1-1-2-1 refers to CH1, hinge, and CH3 exons of IgG1 origin, and a CH2 exon of IgG2 origin. (Fig. 3A) . Myeloma IgG2 displayed -30-fold lower activity than did IgG1, probably reflecting a small amount of contaminating cytophilic isotypes in the IgG2 preparation.
To assess the relative contribution of the Fc C region domains and the genetic hinge, combinations of domain and hinge exons were reciprocally exchanged (Fig. 1) . Table 1 summarizes the FcRI binding properties of these molecules as assessed by competitive inhibition assays. Neither the hinge nor the CH3 domain was shown to contribute significantly to the IgG-FcRI interaction, since grafting of an IgGl hinge or CH3 domain on an IgG2 background did not restore measurable activity to the IgG2 subclass within the range of concentrations tested. Conversely, IgGl hybrid molecules containing either an IgG2 hinge or CH3 domain retained full cytophilic activity. In marked contrast, the insertion of an IgGl CH2 domain conferred full cytophilic properties to IgG2 (Fig. 3B) . Indeed, the IgG2-2-1-2 hybrid immunoglobulin was found to bind to the U937 Fc,,RI with an affinity (Ka = 3.77 x 108 ± 0.86 M-1) comparable to that of wild-type IgG1, whereas the reciprocal hybrid molecule IgGl-1-2-1 was totally inactive. All molecules containing an IgG1 CH2 domain were active regardless of the isotypic origin of the hinge or other y-chain C domains. Conversely, all hybrids containing an IgG2 CH2 domain were functionally inactive. In addition, we also observed that the replacement of an IgG1 hinge with its IgG4 counterpart did not affect the activity of the IgGl chimera (Table 1) . Construction, Expression, and Fc1,RI Binding Properties of IgGl, IgG2, and IgG4 CH2 Domain Point Mutants. The existence of striking primary sequence differences in the lower hinge region of IgG1 and IgG2 CH2 domains (Table 2 ) and the indirect evidence that this region may be structurally important for FcRI recognition led us to concentrate on residues 233-238 (Eu numbering) for more detailed analyses. Individual IgG1 residues E233, L234, and L235 of the ELLGGP sequence were systematically substituted with the corresponding IgG2 residues P233, V234, and A235, respectively. In addition, IgGl G237 was deleted, since there is no corresponding residue at position 237 in IgG2. A similar mutagenesis strategy was also used to modify the N-terminal region of the IgG2 CH2 domain. Residues P233, V234, and L235 of the IgG2 PVAG-P sequence were replaced with the corresponding IgG1 residues E, L, and L, respectively. In addition, a glycine residue was inserted at position 237. Multiple substitutions were also performed such that in all, a panel of 12 IgG1 and IgG2 analogues with mutated CH2 domains were generated. The amino acid sequences of these variants, and an additional IgG4 F234 to L234 mutant molecule, are shown in Table 2 . SDS/PAGE analysis revealed covalent H2L2 assembly in all cases. The electrophoretic patterns for three critical mutants are shown in Fig. 2 . The relative binding activities of the mutated molecules obtained from two independent transfections were compared in binding inhibition assays at two different concentrations of chimeric inhibitor ( Proc. Natl. Acad. Sci. USA 88 (1991) tions of the myeloma 125I-labeled IgG1 (1251-IgGl) tracer (Fig.   4A ). Single substitutions at positions 233 (P for E) or 235 (A for L) completely abolished IgG1 cytophiic activity, as did the deletion of G237. The relatively conservative V for L substitution at position 234 yielded a molecule with reduced activity. This molecule, when examined more closely in a full binding-inhibition assay, displayed a 2-fold decrease in apparent Ka ( Fig. 4B; Table 2 ). Although single mutations introduced in IgGl between residues 233 and 238 reduced or abolished its functional activity, interestingly, none of the reciprocal mutations conferred any significant binding affinity to IgG2 ( Fig. 4A; Table 2 ). Consequently, progressive mutations were sequentially introduced in IgG2 to gradually reconstruct the IgG1 ELLGGP sequence. Only simultaneous substitutions of L at positions 234 and 235, along with the insertion of G at position 237 (PLLGGP) restored binding affinity to a level comparable to that of wild-type IgG1. A representative binding inhibition curve obtained for this triple mutant is shown in Fig. 4B . The Ka was estimated to be 5.17 x 108 ± 0.39 M-1. Reconstruction of the IgG1-like ELLGGP sequence on an IgG4 background through the single F234 to L234 substitution yielded a cytophilic molecule with a binding affinity indistinguishable from that of IgG1 ( Fig. 4A ; Table  2 ). Finally, grafting of the entire IgG1 ELLGGP motif on an IgG2 background yielded a mutated molecule that was -4 times more active than wild-type IgG1 (Ka = 1.65 x 109 ± 0.55 M-1; Fig. 4B ; Table 2 ).
DISCUSSION
Human IgG subclasses differ with respect to their cytophilic properties. The objective of this study was to identify the amino acid residues that play a critical role in the IgGl-Fc,,RI interaction.
As a first step, we engineered a panel of IgG1/IgG2 antibodies by reciprocal exon shuffling to identify the homology region of IgG1 responsible for its interaction with FcXRI on U937 cells. We first demonstrated that the binding affinities of the chimeric IgG1 and IgG2 molecules were indistinguishable from those of their human myeloma counterparts (8) .
The genetic hinges of IgG1 (15 residues) and IgG2 (12 residues), which include the upper and core regions of the "functional hinge" differ by three amino acids in length and by their primary sequences. However, reciprocal shuffling of hinge regions between IgG1 and IgG2 subclasses and the grafting of an IgG4 hinge onto an IgG1 background did not affect the FcXRI binding properties of the parent molecules.
These findings strongly suggest that neither the length of the upper hinge, which restricts segmental flexibility (24) , nor the amino acid sequence of the core hinge modulates cytophilic activity. In addition, it has been shown that this effector function is not affected by reduction of the hinge disulfide bridges (15) . However, it requires the presence of a spacer between the Fab arms and the Fc region since the hingedeleted IgG1 paraprotein Dob does not bind to FcyRI on monocytes (10) .
Reciprocal exchange of CH3 domains, which differ by only one conservative substitution, did not affect the binding properties of the native molecules. Our results are in agreement with the findings that noncovalent pFc' dimers (10) and monoclonal anti-CH3 antibodies are unable to inhibit the binding of IgG1 to the monocyte FcRI (9) .
Reciprocal shuffling of CH2 domains between the IgG1 and IgG2 subclasses unambiguously revealed that the FcRI binding site is an intrinsic property of the IgG1 CH2 domain, since all IgG2 hybrid molecules containing an IgG1 CH2 domain are as active as wild-type IgG1. Furthermore, cytophilic activity was abolished in all IgG1 hybrids containing an IgG2 CH2 domain. These results are consistent with indirect evidence that the CH2 domain is the primary site for Immunology: Chappel et al.
Proc. Natl. Acad. Sci. USA 88 (1991) recognition. Covalent IgG1 CH2 domain dimers retain 85% of the cytophilic activity of the parent molecule (11) , whereas the CH2 domain-deleted paraprotein IgG1 TIM is devoid of activity (10) . Furthermore, monoclonal anti-CH2 antibodies inhibit the IgG1-FcXRI interaction (9) . Recently, reciprocal domain and hinge exchange experiments between human IgG1 and IgE showed that both the IgG1 CH2 and CH3
domains were required to restore full FcXRI binding activity to IgE (14) . Based on free energy calculations, it was concluded that the IgG1 CH2 domain contributes -75% of the free energy gain associated with the IgGl-FcXRI interaction.
Several lines of evidence suggest that the activity of the FcRI binding site depends on its conformation. Grafting an IgG1 CH2 domain onto an IgE background did not restore FcRI binding activity to IgE (14) despite its free energy contribution to the FcrRi interaction. The affinity of bispecific mouse IgG2a/IgG2b hybrid antibodies suggests that only one cytophilic H chain is required for the IgGl-FcRI interaction (13) . However, the findings that only dimeric isolated CH2 domains are cytophilic (12) and that the CH3 domain-deleted IgGi paraprotein SIZ fails to bind FcXRI (10) infer that quaternary interactions between the domains are required to stabilize the active conformation of the IgG1 effector site. Furthermore, inactive aglycosylated IgG1 displays significantly enhanced sensitivity to pepsin and chymotrypsin (25) . Since thesle enzymes cleave within the CH2 domain, these findings suggest that carbohydrates maintain its conformation and stabilize the FcXRI binding site (8) .
The most striking primary sequence differences between IgG1 and IgG2 CH2 domains are clustered in the lower hinge region (residues 233-238) encoded by the CH2 exon. A conserved LLGGP motif between positions 234 and 238 is found in all cytophilic IgG subclasses. The functional importance of the crystallographically defined "upper region" of the CH2 domain is supported by the finding that inactive aglycosylated IgG3 Fc fragments show structural perturbations, as assessed by 1H NMR, in the vicinity of the H268 reporter group located in the spatial proximity of the lower hinge (25) . In addition, full Fc,,RI binding activity was restored to the inactive mouse IgG2b subclass by reconstructing the LLGGP motif with a single L for E substitution at position 235 (16) . Moreover, recent reports (26, 27) showed that the binding activity of human IgG3 was lost in a panel of single point mutants where L234, L235, and G237 were replaced with A residues. Together, these observations led us to engineer a panel of IgGi and IgG2 chimeras containing single and sequential point mutations in this region. Full binding activity was restored to an IgG2 molecule in which G was inserted at position 237, and V234 and A235 were replaced with their IgG1 counterparts L234 and L235 (IgG2/ PLLGGP), respectively. Interestingly, within the limits of the binding-inhibition assay, none of the individual mutations could restore even partial activity to IgG2, although the single reciprocal mutations in IgG1 significantly diminished or abolished it completely. Our results confirm the prediction that the LLGGP motif is essential for FcrRI recognition (15) . Indeed, an IgG4 mutant containing the ELLGGP motif was found to be as active as wild-type IgG1. Since only a single H chain is required for the FcRI interaction (13) , it is likely that at least the "docking" portion of the binding site is located on a loop or a single flexible strand at the N terminus of the CH2 domain. Unfortunately, the protein segment containing the LLGGP sequence yielded no electron density in the x-ray crystallographic structure of human IgG1 Fc (28) .
Interestingly, grafting of the ELLGGP motif onto IgG2 resulted in a molecule 4-fold more active than native IgGi. Although both the PLLGGP and the ELLGGP motifs restored activity to IgG2, only the ELLGGP sequence conferred full binding activity to IgG1. To rationalize these observations, it is necessary to propose the existence of "secondary" IgG2 FcXRI binding sites, which are either nonexistent in IgG1 or are more active than their IgG1 counterparts. These sites probably reside in the IgG2 CH2 domain, since none ofthe shuffled IgGi constructs displayed enhanced binding activity. IgG1 and IgG2 CH2 domains diverge at five residues in their C-terminal halves. Whether these divergent residues contribute to a "secondary" interaction site between CH2 and FcXRI remains to be investigated.
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